Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer

Table 1 The clinical and treatment characteristics of the patients (n = 173)

Characteristics	n (%)
AJCC 2010 T stage
T1	3 (2)
T2a	74 (43)
T2b	14 (8)
T2c	16 (9)
T3a	49 (28)
T3b	17 (10)
Gleason score (median)	7 (3-9)
Initial PSA (median)	14 ng/dL (2-100 ng/dL)
D’Amico risk group
Intermediate	52 (30)
High	121 (70)
Perineural invasion
Absent	103 (60)
Present	56 (32)
Unknown	14 (8)
Percent positive core biopsy percentage
≤ 50 %	76 (44)
> 50%	59 (34)
Unknown	38 (22)
Radiotherapy dose
736 Gy	145 (84)
76 Gy	16 (16)

T: Tumor.

Table 2 Multivariate analysis for independent predictors of biochemical failure free survival

	P value	HR	95%CI for HR
			Lower	Upper
LHRHa type	0.757	0.0	0.0	1.24E+19
D'Amico risk group (ref: intermediate)	0.397	1.5	0.6	3.89E+00
AJCC 2010 T stage (ref: T1)	0.953
T2a	0.909	2869.3	0.0	2.85E+62
T2b	0.915	1646.5	0.0	1.64E+62
T2c	0.912	2150.3	0.0	2.14E+62
T3a	0.91	2583.9	0.0	2.57E+62
T3b	0.908	3108.0	0.0	3.10E+62
Gleason score (ref: ≤ 6)	0.799
7	0.932	1.0	0.5	1.99E+00
≥ 8	0.564	1.3	0.6	2.71E+00

LHRHa: Luteinizing Hormone-Releasing Hormone analog; AJCC: American Joint Committee on Cancer; T: Tumor.

Table 3 Receiver operating characteristic curve analysis for two cut-off values of castrate testosterone levels

	AUC	SE	P value	Sensitivity	Specificity
Castrate level testosteron (≤ 20)	0.628	0.049	0.011	63.6%	62.0%
Castrate level testosteron (< 50)	0.582	0.052	0.107	31.8%	84.5%

AUC: Area under curve.

Table 4 Comparison of studies analyzing the effect of castrate testosterone levels in intermediate and high risk prostate cancer patients receiving androgen deprivation treatment and definitive radiotherapy

	Bryant et al[15]	Nabid et al[16]	Current study
Time	2000-2015	2000-2010	1998-2011
Patient number	764	796	173
Hormone treatment	ADT+/- AA	ADT+/- AA	ADT+AA
Follow up (yr)	5.27	9.15	10.4
RT dose	Unknown	Unknown	73.4-76 Gy
RT technique	Unknown	Unknown	3DCRT-IMRT
Biochemical relapse rate
< 20 ng/dL	18.3% (10 yr)	20.8%	17% (10 year)
20-49 ng/dL	28.1% (10 yr)	24.9%	35% (10 year)

ADT: Androgen deprivation treatment; AA: Antiandrogen; RT: Radiotherapy; 3DCRT: 3 dimensional conformal radiotherapy; IMRT: Intensity modulated radiotherapy.